MIRUM PHARMACEUTICALS INC
NASDAQ: MIRM (Mirum Pharmaceuticals, Inc.)
最近更新时间: 1小时之前69.16
-1.28 (-1.81%)
| 前收盘价格 | 70.44 |
| 收盘价格 | 70.87 |
| 成交量 | 395,858 |
| 平均成交量 (3个月) | 701,798 |
| 市值 | 3,554,380,032 |
| 预期市盈率 (P/E Forward) | 833.33 |
| 价格/销量 (P/S) | 7.47 |
| 股市价格/股市净资产 (P/B) | 12.57 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业毛利率 | -20.39% |
| 营业利益率 (TTM) | -13.61% |
| 稀释每股收益 (EPS TTM) | -1.61 |
| 季度收入增长率 (YOY) | 61.20% |
| 总债务/股东权益 (D/E MRQ) | 135.97% |
| 流动比率 (MRQ) | 3.22 |
| 营业现金流 (OCF TTM) | -6.85 M |
| 杠杆自由现金流 (LFCF TTM) | -23.97 M |
| 资产报酬率 (ROA TTM) | -7.11% |
| 股东权益报酬率 (ROE TTM) | -33.06% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Mirum Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 1.00 |
|
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.90% |
| 机构持股比例 | 114.19% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 6,795,121 |
| Eventide Asset Management, Llc | 30 Sep 2025 | 2,522,563 |
| Novo Holdings A/S | 30 Sep 2025 | 1,264,028 |
| Tang Capital Management Llc | 30 Sep 2025 | 1,236,027 |
| Clearbridge Investments, Llc | 30 Sep 2025 | 1,003,803 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 820,552 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 95.00 (Cantor Fitzgerald, 37.36%) | 购买 |
| 95.00 (Citizens, 37.36%) | 购买 | |
| 95.00 (TD Cowen, 37.36%) | 购买 | |
| 中 | 88.00 (27.24%) | |
| 低 | 77.00 (JP Morgan, 11.34%) | 购买 |
| 平均值 | 87.33 (26.27%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 72.21 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 05 Nov 2025 | 95.00 (37.36%) | 购买 | 70.09 |
| Citizens | 05 Nov 2025 | 95.00 (37.36%) | 购买 | 70.09 |
| HC Wainwright & Co. | 05 Nov 2025 | 81.00 (17.12%) | 购买 | 70.09 |
| Morgan Stanley | 16 Oct 2025 | 81.00 (17.12%) | 购买 | 74.42 |
| TD Cowen | 24 Sep 2025 | 95.00 (37.36%) | 购买 | 74.26 |
| JP Morgan | 12 Sep 2025 | 77.00 (11.34%) | 购买 | 74.31 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合